OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics
OSE and MAbSilico joined their efforts to demonstrate the power of a fully computational
in silico Antibody Discovery and Design platform. The expanded collaboration agreement will now be applied to 10 antibody programs.
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005756/en/
OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) today announced a new collaboration agreement with MAbSilico, a deep technology innovative TechBio located in Tours, France, to use artificial intelligence (AI)-based software for therapeutic monoclonal antibody drug development.
Posted January 26th, 2021 for Biodesix
Important New Findings Validate Testing Strategies That Support Decision Making for Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC)
BOULDER, CO, January 26, 2021 –Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clinical studies will be featured at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC), scheduled for January 28-31, 2021. Findings from these recent studies demonstrate that an individual patient’s immune profile can provide information to support treatment decisions for patients diagnosed with advanced non-small cell lung cancer (NSCLC).
Share this article
Share this article
SAN DIEGO, Jan. 25, 2021 /PRNewswire/ NEUVOGEN, an immunoncology company, is pleased to appoint Christian Ottensmeier MD, PhD, FRCP Head of our Scientific Advisory Board ( SAB ). NEUVOGEN s technology platform differs from other immune priming technologies developed for solid tumors by virtue of its unprecedented breadth accompanied by an impressive adjuvant strategy, said Dr. Christian Ottensmeier, Head of the NEUVOGEN Scientific Advisory Board. Even if only a fraction of the targets primed by their vaccine are translated into primed T cells, the vaccine breadth will still exceed what is possible with other modalities.
Ottensmeier continued, NEUVOGEN s preclinical data demonstrates (in vitro) that their proprietary adjuvant strategy is able to prime against self-proteins preferentially expressed by tumors, opening the possibility that the vaccine may overcome peripheral tolerance. Furthermore, NEUVOGEN s preclinical demonstr
TACTI-002 study expanded in lung cancer
New phase II trial in head and neck cancer announced
EOC Pharma starts new phase II study in metastatic breast cancer
Robust operational and financial position, with $54.9 million in cash as at 31 December 2020, providing cash runway beyond the end of calendar year 2022
Sydney, AUSTRALIA, Jan. 22, 2021 (GLOBE NEWSWIRE) Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (“efti” or “IMP321”) and IMP761, and the activities of its partners.